

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **HANGZHOU TIGERMED CONSULTING CO., LTD.**

### **杭州泰格醫藥科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3347)**

### **INSIDE INFORMATION**

### **LETTER OF INTENT IN RELATION TO PROPOSED COOPERATION**

This announcement is made by Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

### **THE PROPOSED COOPERATION**

The Company hereby announces that on June 11, 2021, the Company entered into a letter of intent (the “**Letter of Intent**”) with Hangzhou State-owned Capital Investment and Operation Co., Ltd.\* (杭州市國有資本投資運營有限公司), Hangzhou Hi-Tech Investment Co., Ltd.\* (杭州高新創業投資有限公司) (collectively, the “**JV Parties**”) and Hangzhou Tailong Venture Investment Partnership (Limited Partnership)\* (杭州泰瓏創業投資合夥企業(有限合夥)) (“**HZ Tailong**”).

Pursuant to the Letter of Intent, the Company, HZ Tailong and the JV Parties proposed to establish a limited partnership in the PRC to invest in life and health industry (the “**Fund**”). It is proposed that the scale of the Fund shall be RMB20 billion which will be contributed by the Company and HZ Tailong as to RMB9.8 billion, RMB0.2 billion and each of the JV Parties as to RMB5 billion respectively. The Fund shall focus on the investment in enterprises involved in hi-tech medical equipment, biopharmaceutical, medicare services, medicare informatization, digital therapeutics and intelligent manufacturing (the “**Proposed Cooperation**”). It is also proposed that HZ Tailong shall act as the manager of the Fund upon its incorporation and a strategic investment committee shall be established for decision making on investments and relevant exits. The Fund is proposed to operate for 12 years of which the initial five years shall be the investment period while the next five years shall be the exit period and the last two years shall be used as buffer in case any investment(s) cannot be exited in time.

## **REASONS FOR THE PROPOSED COOPERATION**

By investing in the Fund, the Company's strong investment and financing platform can be utilized to deepen the Company's layout in the biopharmaceutical field, promote the optimization of upstream and downstream industrial chain and in turn enhance the Company's core competitiveness. Such investment complements the Company's long term investment strategy are in the interest of the shareholders of the Company and the Company as a whole.

## **INFORMATION RELATING TO THE COMPANY AND HZ TAILONG**

The Company is principally engaged in the provision of one-stop and professional clinical research services for innovative drugs, medical devices and biotechnology related products to domestic and international enterprises engaged in providing innovative drugs and medical devices. The Group is a leading China-based provider of comprehensive biopharmaceutical research and development services, with an expanding global presence.

HZ Tailong is a limited partnership incorporated in the PRC in which Hangzhou Tigermed Equity Investment Partnership (Limited Partnership)\* (杭州泰格股權投資合夥企業(有限合夥)), a wholly-owned subsidiary of the Company is a limited partner holding 99% interest and Zhaotai (Zibo) Startup Investment Management Partnership (Limited Partnership)\* (昭泰(淄博)創業投資管理合夥企業(有限合夥)), an independent third party of the Company, is the general partner holding 1% interest. HZ Tailong is principally engaged in provision of private equity investment fund management services and startup company investment fund management services.

## **INFORMATION ON THE JV PARTIES**

Hangzhou State-owned Capital Investment and Operation Co., Ltd.\* (杭州市國有資本投資運營有限公司) is a company established under the law of the PRC with limited liability and is principally engaged in state-owned assets management within the scope authorized by Hangzhou Municipal Government, investment, investment management and consulting services, asset management and disposal, equity management and equity investment fund management.

Hangzhou Hi-Tech Investment Co., Ltd.\* (杭州高新創業投資有限公司) is a company established under the law of the PRC with limited liability and is principally engaged in startup company investment, provision of investment consultation services and provision of startup company management services.

The JV Parties, their respective ultimate beneficial owner(s) and their respective associate(s) are independent third parties of the Company and its connected person.

## **GENERAL**

The Letter of Intent is a non-binding agreement setting out the general principles of the Proposed Cooperation. Upon the entering into the Letter of Intent, the Company and the JV Parties will use their respective best endeavours to enter into further negotiation with a view to enter into formal and legally binding agreement(s) in relation to the Proposed Cooperation.

## LISTING RULES IMPLICATIONS

The Proposed Cooperation, if materializes, may constitute a major transaction on the part of the Company under the Listing Rules. Further announcements will be made by the Company regarding the Proposed Cooperation in accordance with the Listing Rules.

**The shareholders and potential investors of the Company should note that, the terms of the Proposed Cooperation are still under negotiation and no formal and legally binding agreement in relation to the Proposed Cooperation has been entered into as at the date of this announcement. Accordingly, the Proposed Cooperation contemplated under the Letter of Intent may or may not materialize. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Hangzhou Tigermed Consulting Co., Ltd.**  
**Ye Xiaoping**  
*Chairman*

Hong Kong, June 11, 2021

*As at the date of this announcement, the executive directors of the Company are Dr. Ye Xiaoping, Ms. Cao Xiaochun and Ms. Yin Zhuan; the independent non-executive directors of the Company are Mr. Zheng Bijun, Dr. Yang Bo and Mr. Liu Kai Yu Kenneth.*

*\* for identification purpose only*